46 results about "Beta-hemolytic streptococcus" patented technology

A reagent is provided for the detection of an exotoxin protein produced by a beta-hemolytic streptococcus bacteria suspected of being present in a host biological fluid collected from a subject. An enzyme inhibitor is present to inhibit rogue protein modification of the substrate to prevent a false positive result of the color change. A kit is provided that is readily usable by an untrained user and merely requires that an element of the kit be contacted with a biological sample and thereafter no further actions are required by the user before a discernable color change is observed with visible or UV light and a positive / negative results reference card.

A reagent for the detection of an extracellular enzymatically active protein produced by a beta-hemolytic streptococcus bacteria found in a host biological fluid includes a proteinaceous substrate or a cholesterol-containing membrane substrate for the extracellular protein. The substrate is nonspecific within the groups of beta-hemolytic streptococcus bacterium and is in contact with an inert solid matrix. Upon reaction between the streptococcus enzymatically activate protein and the substrate, a color change discernable by an unaided human eye results. Extracellular streptococcus protein found in saliva represents a less invasive source of biological fluid for the determination as to whether a host suffers acute pharyngitis.

VACCIN AGAINST GROUP A BETA HEMOLYTIC STREPTOCOCCUS AND RESPECTIVE PROCESS FOR OBTAINING THEREOF, which predicts the production of recombinant protein cloned from the gene emm5, which contains a sequence of oligonucleotides corresponding to 52 and / or 87 amino acid residues capable of protection, isolated after the sequential molecular identification of the epitopes from the M protein carboxy-terminal region, differing in 01 amino acid residue, identified by antibodies and T lymphocytes of health human beings and of patients carriers of rheumatic fever, capable of generating a protective response by antibodies depending on the T lymphocytes; prevention of the development of the autoimmune disease by the selected epitope was evaluated in vitro with T lymphocytes from the cardiac tissue of patients with lesions arising out of rheumatic fever.

The invention belongs to the medical technical field and discloses the application of high-purity in the preparation of antibacterial medicine, antiviral medicine and other medicines. The invention proves the antipyretic, anti-inflammation, immunity enhancement, antibacterial and anti-virus effects of high-purity forsythiaside through the following experiments: (1) the experiment that high-purityforsythiaside has antipyretic effect on fever rats; (2) the experiment that high-purity forsythiaside inhibits xylene-induced mice ear edema, xylene-reduced capillary permeability of mice; (3) the experiment that high-purity forsythiaside increases carbon clearance ability of mice and increases the lymphocyte transformation rate; (4) the experiment that high-purity forsythiaside has vitro anti-influenza A type virus effect and in-vivo anti-respiratory syncytial virus effect; (5) the experiment that high-purity forsythiaside has vitro inhibition effects on beta-hemolytic streptococcus, staphylococcus aureus, streptococcus viridans and staphylococcus epidermidis.

The invention discloses an essential oil composition prepared by performing rectification and compounding processing on the raw materials comprising 4-terpilenol type tea-tree-oil and eucalyptus grandis x e.urophylla essential oil, and provides the formula, a preparation method and the composition content of the essential oil composition; and the composition has antibacterial insecticidal functions. A gas chromatography method is employed to determine the main content. The method is accurate, stable and easy to operate, is adaptable for industrial production demands, and can help to effectively control the quality of the essential oil composition. The essential oil composition has small toxicity, has different levels of inhibition effects on six pathogens comprising staphylococcus aureus, staphylococcus epidermidis, beta hemolytic streptococcus, escherichia coli, pseudomonas aeruginosa and candida albicans which can cause skin infection, and has antibacterial and insecticidal activities. The preparation method is reasonable and stable, short in production period, suitable for industrial production, and good in application prospect.

The invention relates to a traditional Chinese medicine for treating acne and a preparation method thereof, which belong to the field of Chinese traditional medicine. The traditional Chinese medicine of the invention is made from 13 Chinese medicinal herbs such as folium eriobotryae, goldthread, honeysuckle, radix scutellariae, angelica, tree peony bark, salvia miltiorrhiza, rehmanniae root, gardenia, figwort root, thunberg fritillary bulb, cortex mori radicis and prunella vulgaris. The Chinese medincal herbs are compatible and bring out the best in each other, jointly realize the effect of heat clearing and detoxifying, and cooling and activating blood; the traditional Chinese medicine of the invention has obvious antagonism on acute and chronic inflammation, and has notable antibacterial action on the common cutaneous pathologic bacteria such as staphylococcus aureus, staphylococcus epidermis, beta hemolytic streptococcus, Escherichia coli, pseudomonas aeruginosa and propionibacterium, can obviously decrease swelling rate of rat ear acne caused by propionibacterium, has oxidation resistance effect by improving the vitality of catalase and has a certain analgesic activity. The traditional Chinese medicine of the invention has the advantages of short course of treatment, quick action, and no toxic and side effect, which is a good medicine for treating acne.

This invention relates to Ligulatrovine A separated from Ligularia actroviolacea that can prevent and treat diseases related to Staphylococcus aureus and beta hemolytic streptococcus, its pharmaceutical salts and drug composition. Ligulatrovine A has significant inhibitive effect on Gram-positive bacteria, and can prevent and treat diseases such as boil, pustule, pneumonia, osteomyelitis, acute myocarditis, endocarditis, meningitis, mastitis, cystitis, pelvic inflammation, urinary inflammation, prostatitis, bacteremia, or abscess in muscle, skin, urogential region or central nervous system caused by Gram-positive bacteria infection.

The invention discloses the application of the composition of Myrobalan in the preparation of products for preventing and / or treating pig respiratory diseases, and also provides the antibacterial effect of Myrobalan or its extract and its composition, which can effectively inhibit A One or more combinations of beta-hemolytic streptococcus, Haemophilus parasuis, Streptococcus suis, Bordetella, and Pasteurella multocida grow.